orexo.com
Orexo - Startmeta description
http://www.orexo.com/
meta description
http://www.orexo.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Monday
LOAD TIME
3.1 seconds
16x16
32x32
64x64
128x128
160x160
192x192
256x256
Diabact AB
c/o Skri●●●●●●●●Box 6107
Sto●●●olm , SE-102 32
SE
View this contact
Johan Sjobeck
Box●●●107
Sto●●●olm , SE-102 32
SE
View this contact
Johan Sjobeck
PO B●●●●6107
Sto●●●olm , 10232
SE
View this contact
BUY YOUR DOMAIN
21
YEARS
7
MONTHS
23
DAYS
MELBOURNE IT, LTD. D/B/A INTERNET NAMES WORLDWIDE
WHOIS : whois.melbourneit.com
REFERRED : http://www.melbourneit.com
PAGES IN
THIS WEBSITE
13
SSL
EXTERNAL LINKS
85
SITE IP
31.216.35.68
LOAD TIME
3.063 sec
SCORE
6.2
Orexo - Start | orexo.com Reviews
https://orexo.com
meta description
orexo.com
Products - Orexo
http://orexo.com/en/Products
Zubsolv (buprenorphine and naloxone) sublingual tablet (CIII) is indicated for treatment of opioid dependence and should be used as part of a comprehensive treatment plan, which includes counseling and psychosocial support. Abstral is a drug that provides fast and effective treatment of breakthrough pain in cancer patients. It is based on Orexo's sublingual tablet technology and the analgesic fentanyl. Kibion was divested as of April 30, 2015. Read more in the press release.
About Orexo - Orexo
http://orexo.com/en/About-Orexo
Orexo develops improved specialty pharmaceuticals and treatments for new areas of use at a lower cost, in a shorter period of time and at a lower risk by combining known substances with patented proprietary technologies. Edluar is a product for the treatment of short-term insomnia. The specialty pharma company Meda has a global license for Edluar. Kibion was divested as of April 30, 2015. At the end of 2015, the process of identifying a new external partner for OX-MPI was ongoing. Orexo signs license agr...
Teleconference presenting the new induction label for Zubsolv® - Orexo
http://orexo.com/en/Investor-Relations/Calendar/Teleconference-presenting-the-new-induction-label-for-Zubsolv
Teleconference presenting the new induction label for Zubsolv. Teleconference presenting the new induction label for Zubsolv. Orexo invites media, investors and analysts to a teleconference at 1:00pm CET on August 12, 2015,. Where the new induction label will be presented. Nikolaj Sørensen, CEO, and Michael Sumner, Chief Medical Officer, will also take questions to the induction label and the business in general. To access the teleconference, please call a few minutes before the scheduled start at:.
Press - Orexo
http://orexo.com/en/Press-and-media
To the Image archive. Interim Report January-June 2016. Orexo welcomes increased access to treatment for patients with opioid dependence in the US. Orexo signs license agreement with Mundipharma, which obtains ex-US global rights to Zubsolv. Font color=" 3=" font color=" 6=" font size=" middletext=" /span /p p span class=" Annual Report 2015. Pareto Securities Healthcare Seminar. IR and Communications Manager. Mobile: 46 73 064 16 36. 2008-2015 Orexo AB (publ), Contact: info@orexo.com.
Orexo
http://orexo.com/en
July 12, 2016. ORX Aug 31, 2016 1:24 PM CET. 4800 SEK -1.4%. Interim Report January-June 2016. Orexo welcomes increased access to treatment for patients with opioid dependence in the US. Orexo signs license agreement with Mundipharma, which obtains ex-US global rights to Zubsolv. Orexo sees very limited exposure to the UK and the British pound. Pareto Securities Healthcare Seminar. Interim Report January - September 2016. 2008-2015 Orexo AB (publ), Contact: info@orexo.com.
TOTAL PAGES IN THIS WEBSITE
13
Clinical Data | ZUBSOLV® (buprenorphine and naloxone) sublingual tabletsZubsolv
https://www.zubsolv.com/study-006
Dosage & Administration. Find a Waivered Physician. Dosage & Administration. Find a Waivered Physician. Proven clinically comparable to Suboxone. Sublingual film, but with the added benefit of patient-preferred attributes. The largest combination buprenorphine/naloxone opioid dependence trial ever conducted in the United States. A randomized, noninferiority study to assess early treatment efficacy of ZUBSOLV versus Suboxone film and to explore switching between treatments. Retention in treatment at Day 15.
Portfolio Companies - HealthCap
http://www.healthcap.eu/the-investments
Senior and Special Advisors. Actelion is a Swiss biopharmaceutical company focusing on pulmonary arterial hypertension (PAH). The company listed on the Swiss Stock Exchange in 2000. Aerocrine is a medical technology company that develops and commercializes unique, easy-to-use and tailored products for the measurement of nitric oxide (NO) as an inflammatory marker for patients with inflammatory disorders, such as asthma. Aerocrine listed on the Nasdaq OMX Stockholm stock exchange in 2007. Altimmune is a c...
Helpful Links | ZUBSOLV® (buprenorphine and naloxone) sublingual tabletsZubsolv
https://www.zubsolv.com/dependence/helpful-links
Dosage & Administration. How to Take ZUBSOLV. Dosage & Administration. How to Take ZUBSOLV. There are many resources available to you and your support network to better understand and cope with opioid dependence. Some resources, like the American Board of Addiction Medicine and the American Board of Psychiatry and Neurology, can refer you to local addiction specialists and physicians for treatment. Check out some of the recommended sites below. American Board of Addiction Medicine. The American Society o...
Patient Preferred | ZUBSOLV® (buprenorphine and naloxone) sublingual tabletsZubsolv
https://www.zubsolv.com/zubsolv/patient-preferred
Dosage & Administration. How to Take ZUBSOLV. Dosage & Administration. How to Take ZUBSOLV. Patient-preferred treatment attributes such as taste, ease of administration and mouthfeel. To help you take a different path on your journey to recovery. The primary active ingredient in ZUBSOLV is buprenorphine. ZUBSOLV also contains naloxone to deter misuse. Delivers a comparable concentration of active medication as Suboxone. A previously approved buprenorphine/naloxone sublingual (under the tongue) tablet.
About ZUBSOLV® | ZUBSOLV (buprenorphine and naloxone) sublingual tabletsZubsolv
https://www.zubsolv.com/zubsolv
Dosage & Administration. How to Take ZUBSOLV. Dosage & Administration. How to Take ZUBSOLV. An advanced formulation for the treatment of opioid dependence. ZUBSOLV (buprenorphine and naloxone) sublingual tablets (CIII). ZUBSOLV is a medication for adults with opioid dependence. ZUBSOLV should be used as part of a complete treatment plan that also includes counseling and behavioral therapy. Delivers a comparable concentration of active medication to previously approved Suboxone. FIND A DOCTOR IN YOUR AREA.
About Dependence | ZUBSOLV® (buprenorphine and naloxone) sublingual tabletsZubsolv
https://www.zubsolv.com/dependence
Dosage & Administration. How to Take ZUBSOLV. Dosage & Administration. How to Take ZUBSOLV. A growing, but treatable, problem. According to SAMHSA,* an estimated 5.1 million people in the United States are currently misusing. Opioid prescription drugs that is almost as many people as the populations of Chicago, Philadelphia, and Dallas combined. Approximately 2 million are considered to have opioid dependence. The Substance Abuse and Mental Health Services Administration. Ask your doctor about ZUBSOLV!
RISE™ | ZUBSOLV® (buprenorphine and naloxone) sublingual tabletsZubsolv
https://www.zubsolv.com/zubsolv/rise
Dosage & Administration. How to Take ZUBSOLV. Dosage & Administration. How to Take ZUBSOLV. To take control of your recovery. Everyone is different…so why should treatment plans be the same? RISE was designed to meet your needs and the needs of your support team. Choose from a selection of online tools, resources and build the plan you feel is most helpful to your recovery. LEARN MORE ABOUT RISE. With RISE you can:. Choose the tools and resources you feel best suit your needs. LEARN MORE ABOUT RISE.
Safety/Tolerability | ZUBSOLV® (buprenorphine and naloxone) sublingual tabletsZubsolv
https://www.zubsolv.com/zubsolv/safetytolerability
Dosage & Administration. How to Take ZUBSOLV. Dosage & Administration. How to Take ZUBSOLV. ZUBSOLV is not recommended for initiation of treatment in patients with moderate hepatic impairment due to the increased risk of precipitated withdrawal. However, ZUBSOLV may be used with caution for maintenance treatment in patients with moderate hepatic impairment who have initiated treatment on a buprenorphine product without naloxone. What is the most important information I should know about ZUBSOLV? Buprenor...
Disease Awareness | ZUBSOLV® (buprenorphine and naloxone) sublingual tabletsZubsolv
https://www.zubsolv.com/dependence/disease-awareness
Dosage & Administration. How to Take ZUBSOLV. Dosage & Administration. How to Take ZUBSOLV. Opioid dependence: What you need to know. What are common prescription opioids? Brand Names As of 1/21/15 according to the United States Patent and Trademark Office. With codeine, Robitussin A-C. With codeine (Tylenol #3). This is not a comprehensive list. Withdrawn from US market November 2010. All brand names cited above are the property of their respective owners. Vicodin is a registered trademark of AbbVie Inc.
TOTAL LINKS TO THIS WEBSITE
85
Name.com: Website Unavailable
This page cannot be loaded. This may be due to one of the following reasons:. The IP address has changed. The IP address for this domain may have changed recently. It can take 8-24 hours for DNS changes to propagate. If the page still does not load, check your DNS settings to verify that the domain is set up correctly. Or, you can attempt to restore access to this site by following these instructions. For clearing your DNS cache. There has been a server misconfiguration.
Blog de orexmo - Moi aussi, je t'entends. - Skyrock.com
Mot de passe :. J'ai oublié mon mot de passe. Moi aussi, je t'entends. Il fait froid cette nuit, est-ce que tu m’entends de l’endroit où je suis? Dresse toi et écoute le vent, peut-être entendra-tu mes pleurs. Mais rassure toi, ce sont des pleurs de joies. Dans 5 jours je serais à Berlin, alors attends moi d’ici-là…. Sebastian à qui tu manques sincèrement. Umi Natsuko est fier de vous présenter sa première fiction sur un groupe très apprécié : Cinema Bizarre! Mise à jour :. Abonne-toi à mon blog! Que pou...
OREX MOTORSPORTS
51652 NISSAN SKYLINE 2000. SWC Eco Yellow Stitch. 51411 '08 NISSAN GTR. LICENSE PLATE FRAME - CRYSTAL.
Login
Log in to EPiServer CMS 6. Enable automatic logon to this website. If you log in, cookies will be used. A cookie containing login information will be sent to your web browser. If you do not want to receive cookies, you will be unable to log into the website.
Orexo
Interim Report Jan-June 2015. ORX Aug 11, 2015 5:29 PM CET. 6050 SEK 14.7%. US FDA Approves ZUBSOLV for Induction of Buprenorphine Maintenance Therapy in Patients Suffering from Opioid Dependence. ZUBSOLV Market Access Update on Agreement with CVS Caremark and Announcement of New Exclusive Agreement in Managed Medicaid. Number of shares and votes in Orexo. Interim report January-June 2015. Teleconference presenting the new induction label for Zubsolv. Interim Report January-September 2015.
Orexo - Start
Orexo is a fully integrated specialty pharmaceutical company. Board of Directors and Management. Our drug delivery technologies improve pharmaceuticals. Partnerships are critical to our success. We will be recognized for the added value our products bring to patients and societies. Orexo’s share is listed on Nasdaq Stockholm Mid Cap and available as American Depository Receipts (ADRs) on OTCQX in the US. Financial calendar and events. Reports, presentations and audiocasts. Follow Orexo in social media.
Orexo
Interim Report Jan-June 2015. ORX Aug 11, 2015 5:29 PM CET. 6050 SEK 14.7%. US FDA Approves ZUBSOLV for Induction of Buprenorphine Maintenance Therapy in Patients Suffering from Opioid Dependence. ZUBSOLV Market Access Update on Agreement with CVS Caremark and Announcement of New Exclusive Agreement in Managed Medicaid. Number of shares and votes in Orexo. Interim report January-June 2015. Teleconference presenting the new induction label for Zubsolv. Interim Report January-September 2015.
Orexo
Interim Report Jan-June 2015. ORX Aug 11, 2015 5:29 PM CET. 6050 SEK 14.7%. US FDA Approves ZUBSOLV for Induction of Buprenorphine Maintenance Therapy in Patients Suffering from Opioid Dependence. ZUBSOLV Market Access Update on Agreement with CVS Caremark and Announcement of New Exclusive Agreement in Managed Medicaid. Number of shares and votes in Orexo. Interim report January-June 2015. Teleconference presenting the new induction label for Zubsolv. Interim Report January-September 2015.
Orexo
Interim Report Jan-June 2015. ORX Aug 11, 2015 5:29 PM CET. 6050 SEK 14.7%. US FDA Approves ZUBSOLV for Induction of Buprenorphine Maintenance Therapy in Patients Suffering from Opioid Dependence. ZUBSOLV Market Access Update on Agreement with CVS Caremark and Announcement of New Exclusive Agreement in Managed Medicaid. Number of shares and votes in Orexo. Interim report January-June 2015. Teleconference presenting the new induction label for Zubsolv. Interim Report January-September 2015.
order
Harder, stronger, fuller erections. Easier to achieve erections. Thank you so very much! I am getting the biggest, hardest erections I have ever had. As soon as lust stirs the brain-wham! I am 40 but am performing better than when I was 18! I ordered with much trepidation, but now go nowhere with out your product-fantastic, thank you! Jeff T. WA. You guys have given me back my confidence to please my wife of 15 years! When we go on vacation now she doesn't allow me to leave home without it. Doug J. CA.
orexonline.net - orexonline Resources and Information.
This webpage was generated by the domain owner using Sedo Domain Parking. Disclaimer: Sedo maintains no relationship with third party advertisers. Reference to any specific service or trade mark is not controlled by Sedo nor does it constitute or imply its association, endorsement or recommendation.
SOCIAL ENGAGEMENT